AZD4573, a CDK9 inhibitor currently under clinical investigation (NCT03263637), was highly potent against all MCL cell lines tested, with an IC50 value of only 4.0–16.6 nM (Additional file 5: Figure S9B). The gene discussed is CDK9; the disease is mantle cell lymphoma.